<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05076656</url>
  </required_header>
  <id_info>
    <org_study_id>EPIGEN-MICROBIOTA</org_study_id>
    <nct_id>NCT05076656</nct_id>
  </id_info>
  <brief_title>Epigenetic and Microbiota Modifications</brief_title>
  <acronym>EPI-MICROBIO</acronym>
  <official_title>Epigenetic and Microbiota Modifications in the Genesis of Adipose Tissue Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to investigate how gut microbiota interventions are able to change gut microbiota&#xD;
      population and impact insulin resistance, 30 type2 diabetes volunteers with obesity will be&#xD;
      randomized to one of the three treatment groups: 1) probiotics arm, who will take a&#xD;
      Lactobacillus fermentum D3 in pills daily; 2) FMT arm, who will take a lyophilized fecal&#xD;
      microbiota transplant in pills; and 3) control group, who will take placebo pills. After 3&#xD;
      months, insulin resistance, glucose metabolism parameters, and gut microbiota variation will&#xD;
      be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in HOMA-IR</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Homeostasis Model Assessment of fasting Insulin Resistance (HOMA-IR: glucose (mmol/l( x insulin (pmol/l)/22.5)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in gut microbiota</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change from baseline in 16S rRNA amplicons after 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose metabolism</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change from baseline in oral glucose tolerance test (OGTT)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes type2</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Probiotics arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who receive a probiotics pill daily: Lactobacillus fermentum D3 (PCT/EP 2012058214)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMT arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals who receive a FMT in the form of pills with fecal material from a healthy donor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Individuals who receive a probiotics pill daily of placebo (milk powder)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus fermentum D3</intervention_name>
    <description>Lactobacillus fermentum D3 in a white, gelatin capsule (orally), with lyophilized L. fermentum D3 without preservatives, sugars, or additives.</description>
    <arm_group_label>Probiotics arm</arm_group_label>
    <other_name>PCT/EP 2012058214</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fecal microbiota transplant (FMT)</intervention_name>
    <description>Fecal microbiota transplant (FMT) in a green, gelatin capsule (orally), with lyophilized fecal material.</description>
    <arm_group_label>FMT arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo in a white, gelatin capsule (orally), with powder milk</description>
    <arm_group_label>Control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type2 diabetes in treatment with metformin&#xD;
&#xD;
          -  30 kg/m2≤IMC≤40 kg/m2&#xD;
&#xD;
          -  30-70 years old&#xD;
&#xD;
          -  HOMA-IR &gt;6&#xD;
&#xD;
          -  Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  psychopathologic alterations that do not permit the adherence to the trial.&#xD;
&#xD;
          -  Diabetes medication different from metformin.&#xD;
&#xD;
          -  History of cholecystectomy.&#xD;
&#xD;
          -  Use of Probiotics, and/or antibiotics in the last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Tinahones, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Investigación Biomédica de Málaga (IBIMA).</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francisco J Tinahones, MD, PhD</last_name>
    <phone>+34 951032647</phone>
    <email>fjtinahones@uma.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Moreno-Indias, PhD</last_name>
    <phone>+34 951032647</phone>
    <email>isabel.moreno@ibima.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J Tinahones, MD, PhD</last_name>
      <phone>+34 951 932 734</phone>
      <email>fjtinahones@uma.es</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>September 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes type2</keyword>
  <keyword>FMT</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

